메뉴 건너뛰기




Volumn 18, Issue 6, 2000, Pages 1193-1202

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group

Author keywords

[No Author keywords available]

Indexed keywords

OXALIPLATIN; PACLITAXEL;

EID: 0034064719     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.6.1193     Document Type: Article
Times cited : (164)

References (60)
  • 1
    • 0027382941 scopus 로고
    • Cancer of the ovary
    • Cannistra SA: Cancer of the ovary. N Engl J Med 329:1550-1559, 1993
    • (1993) N Engl J Med , vol.329 , pp. 1550-1559
    • Cannistra, S.A.1
  • 2
    • 0030054309 scopus 로고    scopus 로고
    • Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
    • McGuire W, Hoskins W, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
    • (1996) N Engl J Med , vol.334 , pp. 1-6
    • McGuire, W.1    Hoskins, W.2    Brady, M.F.3
  • 3
    • 0028237309 scopus 로고
    • Treatment of ovarian cancer: Current status
    • Ozols RF: Treatment of ovarian cancer: Current status. Semin Oncol 21:1-9, 1994
    • (1994) Semin Oncol , vol.21 , pp. 1-9
    • Ozols, R.F.1
  • 5
    • 0027999966 scopus 로고
    • European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
    • Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
    • (1994) J Clin Oncol , vol.12 , pp. 2654-2666
    • Eisenhauer, E.A.1    Ten Bokkel Huinink, W.W.2    Swenerton, K.D.3
  • 6
    • 0009685829 scopus 로고    scopus 로고
    • Is cisplatin-taxol (PT) the standard treatment in advanced ovarian cancer?
    • abstr
    • Bertelsen K, Kaern J, Simonsen E, et al: Is cisplatin-taxol (PT) the standard treatment in advanced ovarian cancer? Eur J Cancer 33:614, 1998 (abstr)
    • (1998) Eur J Cancer , vol.33 , pp. 614
    • Bertelsen, K.1    Kaern, J.2    Simonsen, E.3
  • 7
    • 0030900145 scopus 로고    scopus 로고
    • Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
    • ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997
    • (1997) J Clin Oncol , vol.15 , pp. 2183-2193
    • Ten Bokkel Huinink, W.1    Gore, M.2    Carmichael, J.3
  • 8
    • 0028153230 scopus 로고
    • Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Onclogy Group study
    • Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Onclogy Group study. J Clin Oncol 12:1748-1753, 1994
    • (1994) J Clin Oncol , vol.12 , pp. 1748-1753
    • Thigpen, J.T.1    Blessing, J.A.2    Ball, H.3
  • 9
    • 0026086870 scopus 로고
    • Second-line platinum therapy in patients with previously treated with cisplatin
    • Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
    • (1991) J Clin Oncol , vol.9 , pp. 389-393
    • Markman, M.1    Rothman, R.2    Hakes, T.3
  • 10
    • 0025860057 scopus 로고
    • Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience
    • Omura G, Brady MF, Homesley HD, et al: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol 9:1138-1150, 1991
    • (1991) J Clin Oncol , vol.9 , pp. 1138-1150
    • Omura, G.1    Brady, M.F.2    Homesley, H.D.3
  • 11
    • 0019284266 scopus 로고
    • 1,2-diaminocyclohexane platinum derivatives of potential clinical values
    • Mathé G, Muggia F (eds): Berlin, Springer-Verlag
    • Burchenal J, Irani G, Kern K, et al: 1,2-diaminocyclohexane platinum derivatives of potential clinical values, in Mathé G, Muggia F (eds): Recent Results in Cancer Research: Cancer Chemo-and Immuno-pharmacology. Berlin, Springer-Verlag, 1980, pp 146-155
    • (1980) Recent Results in Cancer Research: Cancer Chemo-and Immuno-pharmacology , pp. 146-155
    • Burchenal, J.1    Irani, G.2    Kern, K.3
  • 12
    • 0027146423 scopus 로고
    • In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin
    • Pendyala L, Creaven PJ: In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53:5970-5976, 1993
    • (1993) Cancer Res , vol.53 , pp. 5970-5976
    • Pendyala, L.1    Creaven, P.J.2
  • 13
    • 0031855988 scopus 로고    scopus 로고
    • Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin
    • Fink D, Nebel S, Norris PS, et al: Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer 77:741-746, 1998
    • (1998) Int J Cancer , vol.77 , pp. 741-746
    • Fink, D.1    Nebel, S.2    Norris, P.S.3
  • 14
    • 0009724281 scopus 로고
    • Cross-resistance patterns of cell lines selected with platinum suggest differences in the activities and mechanisms of resistance of platinum analogues
    • abstr
    • Alvarez M, Ortuzar W, Rixe O, et al: Cross-resistance patterns of cell lines selected with platinum suggest differences in the activities and mechanisms of resistance of platinum analogues. Proc Annu Meet Am Assoc Cancer Res 35:439, 1994 (abstr)
    • (1994) Proc Annu Meet Am Assoc Cancer Res , vol.35 , pp. 439
    • Alvarez, M.1    Ortuzar, W.2    Rixe, O.3
  • 15
    • 0000460127 scopus 로고    scopus 로고
    • Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel
    • Rixe O, Ortuzar W, Alvarez M, et al: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52:1855-1865, 1996
    • (1996) Biochem Pharmacol , vol.52 , pp. 1855-1865
    • Rixe, O.1    Ortuzar, W.2    Alvarez, M.3
  • 16
    • 0000417489 scopus 로고
    • Comparison of the activity of cisplatin (CP) and oxaliplatin (OXALI) alone or in combination in parental and drug resistant sublines
    • abstr
    • Ortuzar W, Paull K, Rixe O, et al: Comparison of the activity of cisplatin (CP) and oxaliplatin (OXALI) alone or in combination in parental and drug resistant sublines. Proc Annu Meet Am Assoc Cancer Res 35:332, 1994 (abstr)
    • (1994) Proc Annu Meet Am Assoc Cancer Res , vol.35 , pp. 332
    • Ortuzar, W.1    Paull, K.2    Rixe, O.3
  • 17
    • 0000360781 scopus 로고
    • Experimental study of three platinum complexes: CDDP, CBDCA and L-OHP on L1210 leukemia - Alternate or simultaneous association of two platinum complexes
    • abstr
    • Mathé G, Chenu E, Bourut C, et al: Experimental study of three platinum complexes: CDDP, CBDCA and L-OHP on L1210 leukemia - Alternate or simultaneous association of two platinum complexes. Proc Annu Meet Am Assoc Cancer Res 30:471, 1989 (abstr)
    • (1989) Proc Annu Meet Am Assoc Cancer Res , vol.30 , pp. 471
    • Mathé, G.1    Chenu, E.2    Bourut, C.3
  • 18
    • 0025020085 scopus 로고
    • Phase I study of oxaliplatin in patients with advanced cancer
    • Extra JM, Espie M, Calvo F, et al: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25: 299-303, 1990
    • (1990) Cancer Chemother Pharmacol , vol.25 , pp. 299-303
    • Extra, J.M.1    Espie, M.2    Calvo, F.3
  • 19
    • 0343046558 scopus 로고
    • Oxaliplatin (L-OHP): Global safety in 682 patients (pts)
    • abstr 933
    • Brienza S, Vignoud J, Itzhaki M, et al: Oxaliplatin (L-OHP): Global safety in 682 patients (pts). Eur J Cancer 31A:S194, 1995 (suppl, abstr 933)
    • (1995) Eur J Cancer , vol.31 A , Issue.SUPPL.
    • Brienza, S.1    Vignoud, J.2    Itzhaki, M.3
  • 20
    • 0000410062 scopus 로고
    • Neurotoxicity (NTX) of long-term oxaliplatin (L-OHP) therapy
    • abstr
    • Brienza S, Fandi A, Hugret F, et al: Neurotoxicity (NTX) of long-term oxaliplatin (L-OHP) therapy. Proc Annu Meet Am Assoc Cancer Res 34:406, 1993 (abstr)
    • (1993) Proc Annu Meet Am Assoc Cancer Res , vol.34 , pp. 406
    • Brienza, S.1    Fandi, A.2    Hugret, F.3
  • 21
    • 8944230189 scopus 로고    scopus 로고
    • Loss of DNA mismatch repair in acquired resistance to cisplatin
    • Aebi S, Kurdihaidar B, Gordon R, et al: Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 53:3087-3090, 1996
    • (1996) Cancer Res , vol.53 , pp. 3087-3090
    • Aebi, S.1    Kurdihaidar, B.2    Gordon, R.3
  • 22
    • 15444350120 scopus 로고    scopus 로고
    • In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair
    • Fink D, Zheng H, Nebel S, et al: In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57:1841-1845, 1997
    • (1997) Cancer Res , vol.57 , pp. 1841-1845
    • Fink, D.1    Zheng, H.2    Nebel, S.3
  • 24
    • 0030480745 scopus 로고    scopus 로고
    • Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer
    • Chollet P, Bensmaine A, Brienza S, et al: Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7:1065-1070, 1996
    • (1996) Ann Oncol , vol.7 , pp. 1065-1070
    • Chollet, P.1    Bensmaine, A.2    Brienza, S.3
  • 25
    • 0016799829 scopus 로고
    • Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials
    • Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 31:103-115, 1975
    • (1975) Biometrics , vol.31 , pp. 103-115
    • Pocock, S.J.1    Simon, R.2
  • 26
    • 0019365237 scopus 로고
    • Reporting results of cancer treatment
    • Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
    • (1981) Cancer , vol.47 , pp. 207-214
    • Miller, A.B.1    Hoogstraten, B.2    Staquet, M.3
  • 27
    • 0030698757 scopus 로고    scopus 로고
    • Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients
    • Eisenhauer EA, Vermorken JB, van Glabbeke M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. Ann Oncol 8:963-968, 1997
    • (1997) Ann Oncol , vol.8 , pp. 963-968
    • Eisenhauer, E.A.1    Vermorken, J.B.2    Van Glabbeke, M.3
  • 28
    • 10544229791 scopus 로고    scopus 로고
    • Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
    • Creemers GJ, Bolis G, Gore M, et al: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 14:3056-3061, 1996
    • (1996) J Clin Oncol , vol.14 , pp. 3056-3061
    • Creemers, G.J.1    Bolis, G.2    Gore, M.3
  • 29
    • 0000626027 scopus 로고
    • A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer
    • abstr 769
    • Armstrong D, Rowinsky EK, Donehower R, et al: A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 14:275a, 1995 (abstr 769)
    • (1995) Proc Am Soc Clin Oncol , vol.14
    • Armstrong, D.1    Rowinsky, E.K.2    Donehower, R.3
  • 30
    • 9244247616 scopus 로고    scopus 로고
    • Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma
    • Kudelka A, Tresukosol D, Edwards CL, et al: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14:1552-1557, 1996
    • (1996) J Clin Oncol , vol.14 , pp. 1552-1557
    • Kudelka, A.1    Tresukosol, D.2    Edwards, C.L.3
  • 31
    • 0000391321 scopus 로고    scopus 로고
    • Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group trial
    • abstr 763
    • Gordon A, Bookman MA, Malmstrom H, et al: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group trial. Proc Am Soc Clin Oncol 15:282a, 1996 (abstr 763)
    • (1996) Proc Am Soc Clin Oncol , vol.15
    • Gordon, A.1    Bookman, M.A.2    Malmstrom, H.3
  • 32
    • 0031786482 scopus 로고    scopus 로고
    • Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label, phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
    • Bookman MA, Malmstrom H, Bolis G, et al: Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label, phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16:3345-3352, 1998
    • (1998) J Clin Oncol , vol.16 , pp. 3345-3352
    • Bookman, M.A.1    Malmstrom, H.2    Bolis, G.3
  • 33
    • 0027999654 scopus 로고
    • Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer
    • Francis P, Schneider J, Hann L, et al: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12:2301-2308, 1994
    • (1994) J Clin Oncol , vol.12 , pp. 2301-2308
    • Francis, P.1    Schneider, J.2    Hann, L.3
  • 34
    • 0028900053 scopus 로고
    • Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer
    • Piccart M, Gore M, ten Bokkel Huinink WW, et al: Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87:676-681, 1995
    • (1995) J Natl Cancer Inst , vol.87 , pp. 676-681
    • Piccart, M.1    Gore, M.2    Ten Bokkel Huinink, W.W.3
  • 35
    • 0028810460 scopus 로고
    • Docetaxel in advanced ovarian cancer: Preliminary results from three phase II trials-EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center
    • Kaye SB, Piccart M, Aapro M, et al: Docetaxel in advanced ovarian cancer: Preliminary results from three phase II trials-EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center. Eur J Cancer 31A:S14-S17, 1995 (suppl 4)
    • (1995) Eur J Cancer , vol.31 A , Issue.4 SUPPL.
    • Kaye, S.B.1    Piccart, M.2    Aapro, M.3
  • 36
    • 0027521254 scopus 로고
    • Hexamethylmelamine/ altretamine as second-line therapy for epithelial ovarian carcinoma
    • Moore D, Valea F, Grumpler LS, et al: Hexamethylmelamine/ altretamine as second-line therapy for epithelial ovarian carcinoma. Gynecol Oncol 51:109-112, 1993
    • (1993) Gynecol Oncol , vol.51 , pp. 109-112
    • Moore, D.1    Valea, F.2    Grumpler, L.S.3
  • 37
    • 0031193915 scopus 로고    scopus 로고
    • Hexamethylmelamine as a single second line agent in ovarian cancer: Follow-up report and review of the literature
    • Manetta A, Krishnansu T, Edwards S, et al: Hexamethylmelamine as a single second line agent in ovarian cancer: Follow-up report and review of the literature. Gynecol Oncol 66:20-26, 1997
    • (1997) Gynecol Oncol , vol.66 , pp. 20-26
    • Manetta, A.1    Krishnansu, T.2    Edwards, S.3
  • 38
    • 0027066977 scopus 로고
    • Hexamethylmelamine as second line therapy in platin-resistant ovarian cancer
    • Vergote I, Himmelmann A, Bo Frankendal PH, et al: Hexamethylmelamine as second line therapy in platin-resistant ovarian cancer. Gynecol Oncol 47:282-286, 1992
    • (1992) Gynecol Oncol , vol.47 , pp. 282-286
    • Vergote, I.1    Himmelmann, A.2    Bo Frankendal, P.H.3
  • 39
    • 0032103330 scopus 로고    scopus 로고
    • Altretamine (Hexamethylmelamine) in platinum resistant and platinum refractory ovarian cancer: A Gynecologic Oncology Group phase II trial
    • Markman M, Blessing JA, Moore D, et al: Altretamine (Hexamethylmelamine) in platinum resistant and platinum refractory ovarian cancer: A Gynecologic Oncology Group phase II trial. Gynecol Oncol 69:226-229, 1998
    • (1998) Gynecol Oncol , vol.69 , pp. 226-229
    • Markman, M.1    Blessing, J.A.2    Moore, D.3
  • 40
    • 0031894188 scopus 로고    scopus 로고
    • Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study
    • Rose G, Blessing A, Mayer R, et al: Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 16:405-410, 1998
    • (1998) J Clin Oncol , vol.16 , pp. 405-410
    • Rose, G.1    Blessing, A.2    Mayer, R.3
  • 41
    • 0028088853 scopus 로고
    • Oral etoposide is active against platinum-resistant epithelial ovarian cancer
    • Hoskins J, Swenerton KD: Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12:60-63, 1994
    • (1994) J Clin Oncol , vol.12 , pp. 60-63
    • Hoskins, J.1    Swenerton, K.D.2
  • 42
    • 0027295694 scopus 로고
    • Low-dose oral etoposide in epithelial cancer of the ovary
    • Marzola M, Zuchetti M, Colombo N, et al: Low-dose oral etoposide in epithelial cancer of the ovary. Ann Oncol 4:517-519, 1993
    • (1993) Ann Oncol , vol.4 , pp. 517-519
    • Marzola, M.1    Zuchetti, M.2    Colombo, N.3
  • 43
    • 0026599140 scopus 로고
    • Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease
    • Markman M, Hakes T, Reichman B, et al: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 10:243-248, 1992
    • (1992) J Clin Oncol , vol.10 , pp. 243-248
    • Markman, M.1    Hakes, T.2    Reichman, B.3
  • 44
    • 0024422604 scopus 로고
    • Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group study
    • Sutton GP, Blessing JA, Homesley HD, et al: Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 7:1672-1676, 1989
    • (1989) J Clin Oncol , vol.7 , pp. 1672-1676
    • Sutton, G.P.1    Blessing, J.A.2    Homesley, H.D.3
  • 45
    • 0030757254 scopus 로고    scopus 로고
    • Efficacy of carboplatin plus primary prophylactic filgrastim (granulocyte colony stimulating factor) in relapsed ovarian cancer: A study of the Gynecologic Study Group of the Comprehensive Cancer Center Limburg
    • Wils J, Geuns HV, Wals J, et al: Efficacy of carboplatin plus primary prophylactic filgrastim (granulocyte colony stimulating factor) in relapsed ovarian cancer: A study of the Gynecologic Study Group of the Comprehensive Cancer Center Limburg. Anticancer Drugs 8:432-435, 1997
    • (1997) Anticancer Drugs , vol.8 , pp. 432-435
    • Wils, J.1    Geuns, H.V.2    Wals, J.3
  • 46
    • 0021048258 scopus 로고
    • Phase II study of JM 8, a new platinum analog in advanced ovarian carcinoma
    • Evans BD, Rajo KS, Calvert AH, et al: Phase II study of JM 8, a new platinum analog in advanced ovarian carcinoma. Cancer Treat Rep 67:997-1000, 1983
    • (1983) Cancer Treat Rep , vol.67 , pp. 997-1000
    • Evans, B.D.1    Rajo, K.S.2    Calvert, A.H.3
  • 47
    • 0022514448 scopus 로고
    • Phase II study of carboplatin in patients with ovarian carcinoma: A National Cancer Institute of Canada Trials Groups Study
    • Eisenhauer EA, Swenerton KD, Sturgeon J, et al: Phase II study of carboplatin in patients with ovarian carcinoma: A National Cancer Institute of Canada Trials Groups Study. Cancer Treat Rep 70:1195-1198, 1986
    • (1986) Cancer Treat Rep , vol.70 , pp. 1195-1198
    • Eisenhauer, E.A.1    Swenerton, K.D.2    Sturgeon, J.3
  • 48
    • 0028020890 scopus 로고
    • Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients
    • Lund B, Hansen OP, Theilade K, et al: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86:1530-1533, 1994
    • (1994) J Natl Cancer Inst , vol.86 , pp. 1530-1533
    • Lund, B.1    Hansen, O.P.2    Theilade, K.3
  • 49
    • 0000707103 scopus 로고    scopus 로고
    • Phase III of cisplatin (P) or paclitaxel (T), versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study #132
    • abstr 1257
    • Muggia F, Braly P, Brady MF, et al: Phase III of cisplatin (P) or paclitaxel (T), versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study #132. Proc Am Soc Clin Oncol 16:352a, 1997 (abstr 1257)
    • (1997) Proc Am Soc Clin Oncol , vol.16
    • Muggia, F.1    Braly, P.2    Brady, M.F.3
  • 50
    • 9544238078 scopus 로고    scopus 로고
    • Phase D study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum-resistant disease
    • Bajetta E, Di Leo A, Biganzoli L, et al: Phase D study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 14:2546-2551, 1996
    • (1996) J Clin Oncol , vol.14 , pp. 2546-2551
    • Bajetta, E.1    Di Leo, A.2    Biganzoli, L.3
  • 51
    • 0011811413 scopus 로고
    • Phase I study of irinotecan (cpt-11) in combination with cisplatin (cddp) on cervical carcinoma
    • abstr
    • Sugiyama T, Takeuchi S, Yakushiji M: Phase I study of irinotecan (cpt-11) in combination with cisplatin (cddp) on cervical carcinoma. Proc Am Soc Clin Oncol 13:856a, 1994 (abstr)
    • (1994) Proc Am Soc Clin Oncol , vol.13
    • Sugiyama, T.1    Takeuchi, S.2    Yakushiji, M.3
  • 52
    • 0003182226 scopus 로고
    • Gemcitabine (GEM) in cisplatin-resistant ovarian cancer
    • abstr
    • Kaufmann M, Bauknecht T, Jonat W, et al: Gemcitabine (GEM) in cisplatin-resistant ovarian cancer. Proc Am Soc Clin Oncol 14:272a, 1994 (abstr)
    • (1994) Proc Am Soc Clin Oncol , vol.14
    • Kaufmann, M.1    Bauknecht, T.2    Jonat, W.3
  • 53
    • 0004482591 scopus 로고    scopus 로고
    • A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer
    • abstr
    • Underbill C, Parnis FX, Highley M, et al: A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 15:290a, 1996 (abstr)
    • (1996) Proc Am Soc Clin Oncol , vol.15
    • Underbill, C.1    Parnis, F.X.2    Highley, M.3
  • 54
    • 0028330988 scopus 로고
    • High-dose intensity regimens with epirubicin in ovarian cancer
    • Vermorken JB, Bolis G, Van Rijswijk REN, et al: High-dose intensity regimens with epirubicin in ovarian cancer. Semin Oncol 21:17-22, 1994
    • (1994) Semin Oncol , vol.21 , pp. 17-22
    • Vermorken, J.B.1    Bolis, G.2    Van Rijswijk, R.E.N.3
  • 55
    • 0003195061 scopus 로고    scopus 로고
    • Oxaliplatin (L-OHP) phase II study in platinum (PT) pretreated advanced ovarian cancer (AOC): Preliminary results
    • abstr 1405
    • Dieras V, Bougnoux P, Petit T, et al: Oxaliplatin (L-OHP) phase II study in platinum (PT) pretreated advanced ovarian cancer (AOC): Preliminary results. Proc Am Soc Clin Oncol 17:364a, 1998 (abstr 1405)
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Dieras, V.1    Bougnoux, P.2    Petit, T.3
  • 56
    • 0032859533 scopus 로고    scopus 로고
    • Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate use experience
    • Faivre S, Kalla S, Cvitkovic E, et al: Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate use experience. Ann Oncol 10:1125-1128, 1999
    • (1999) Ann Oncol , vol.10 , pp. 1125-1128
    • Faivre, S.1    Kalla, S.2    Cvitkovic, E.3
  • 57
    • 0003610856 scopus 로고    scopus 로고
    • Paclitaxel (PXL)-oxaliplatin (L-OHP): A feasible active combination in heavily pretreated advanced ovarian carcinoma (ADOVCA) patients (PTS)
    • abstr 1378
    • Kalla S, Faivre S, Bensmaine A, et al: Paclitaxel (PXL)-oxaliplatin (L-OHP): A feasible active combination in heavily pretreated advanced ovarian carcinoma (ADOVCA) patients (PTS). Proc Am Soc Clin Oncol 17:357a, 1998 (abstr 1378)
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Kalla, S.1    Faivre, S.2    Bensmaine, A.3
  • 58
    • 0001430095 scopus 로고    scopus 로고
    • Multicentric phase H-III trial of oxaliplatin (LOHP) versus cisplatin (P) both in association with cyclophosphamide (C) in the treatment of advanced ovarian cancer (AOC): Toxicity efficacy results
    • abstr 1266
    • Misset J, Chollet P, Vennin P, et al: Multicentric phase H-III trial of oxaliplatin (LOHP) versus cisplatin (P) both in association with cyclophosphamide (C) in the treatment of advanced ovarian cancer (AOC): Toxicity efficacy results. Proc Am Soc Clin Oncol 16:354a, 1997 (abstr 1266)
    • (1997) Proc Am Soc Clin Oncol , vol.16
    • Misset, J.1    Chollet, P.2    Vennin, P.3
  • 59
    • 0343247791 scopus 로고    scopus 로고
    • Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer
    • Soulié P, Bensmaine A, Garrino C, et al: Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 33:1400-1406, 1997
    • (1997) Eur J Cancer , vol.33 , pp. 1400-1406
    • Soulié, P.1    Bensmaine, A.2    Garrino, C.3
  • 60
    • 0003528777 scopus 로고    scopus 로고
    • Feasability study of the paclitaxel (PXL), oxaliplatin (LOHP) and cisplatin (CDDP) combination in advanced ovarian cancer (AOC) patients (PTS)
    • abstr 1409
    • Delaloge S, Laadem A, Chouaki N, et al: Feasability study of the paclitaxel (PXL), oxaliplatin (LOHP) and cisplatin (CDDP) combination in advanced ovarian cancer (AOC) patients (PTS). Proc Am Soc Clin Oncol 18:365a, 1999 (abstr 1409)
    • (1999) Proc Am Soc Clin Oncol , vol.18
    • Delaloge, S.1    Laadem, A.2    Chouaki, N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.